• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

直接 KRAS G12C 突变抑制剂的研究进展。

The Research Progress of Direct KRAS G12C Mutation Inhibitors.

机构信息

Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.

出版信息

Pathol Oncol Res. 2021 Apr 23;27:631095. doi: 10.3389/pore.2021.631095. eCollection 2021.

DOI:10.3389/pore.2021.631095
PMID:34257597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8262225/
Abstract

KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevant drugs under study and challenges that need to be considered in future research.

摘要

KRAS 突变长期以来被认为是不可成药的。然而，自从最近发现开关 II 口袋以来，已经开发出了一系列直接的 KRAS 突变抑制剂。这篇综述将总结直接 KRAS G12C 突变抑制剂的开发进展，目前正在研究的相关药物以及未来研究中需要考虑的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/d85af01d56f2/pore-27-631095-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/db0f7d6f5818/pore-27-631095-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/58667398a77a/pore-27-631095-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/f1ba7c953bdf/pore-27-631095-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/bfb8816334bf/pore-27-631095-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/27f18ba7f6e6/pore-27-631095-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/1a424f6485e8/pore-27-631095-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/321afff7b855/pore-27-631095-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/d85af01d56f2/pore-27-631095-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/db0f7d6f5818/pore-27-631095-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/58667398a77a/pore-27-631095-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/f1ba7c953bdf/pore-27-631095-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/bfb8816334bf/pore-27-631095-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/27f18ba7f6e6/pore-27-631095-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/1a424f6485e8/pore-27-631095-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/321afff7b855/pore-27-631095-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53fa/8262225/d85af01d56f2/pore-27-631095-g008.jpg

相似文献

1
The Research Progress of Direct KRAS G12C Mutation Inhibitors.直接 KRAS G12C 突变抑制剂的研究进展。
Pathol Oncol Res. 2021 Apr 23;27:631095. doi: 10.3389/pore.2021.631095. eCollection 2021.
2
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?KRAS G12C 权游，谁是 KRAS 抑制剂的铁王座之王？
Cancer Treat Rev. 2020 Mar;84:101974. doi: 10.1016/j.ctrv.2020.101974. Epub 2020 Jan 23.
3
Direct KRAS inhibition: progress, challenges, and a glimpse into the future.直接抑制KRAS：进展、挑战及对未来的展望
Expert Rev Anticancer Ther. 2020 Jun;20(6):437-440. doi: 10.1080/14737140.2020.1760093. Epub 2020 Apr 28.
4
From bench to bedside: current development and emerging trend of KRAS-targeted therapy.从 bench 到 bedside：KRAS 靶向治疗的当前进展与新兴趋势
Acta Pharmacol Sin. 2024 Apr;45(4):686-703. doi: 10.1038/s41401-023-01194-4. Epub 2023 Dec 4.
5
Targeting Kras -mutant cancer with a mutation-specific inhibitor.针对具有突变特异性抑制剂的 Kras 突变型癌症。
J Intern Med. 2020 Aug;288(2):183-191. doi: 10.1111/joim.13057. Epub 2020 Apr 7.
6
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.致癌性 KRAS 阻断治疗：重燃热情与持续挑战。
Mol Cancer. 2021 Oct 4;20(1):128. doi: 10.1186/s12943-021-01422-7.
7
Targeting the KRAS G12C mutation in patients with advanced solid tumors.针对晚期实体瘤患者的KRAS G12C突变
Clin Adv Hematol Oncol. 2019 Nov;17(11):612-614.
8
KRAS mutation: from undruggable to druggable in cancer.KRAS 突变：从不可用药到癌症的可用药。
Signal Transduct Target Ther. 2021 Nov 15;6(1):386. doi: 10.1038/s41392-021-00780-4.
9
KRAS G12C inhibition and innate immune targeting.KRAS G12C 抑制与固有免疫靶向治疗
Expert Opin Ther Targets. 2021 Mar;25(3):167-174. doi: 10.1080/14728222.2021.1902991. Epub 2021 Mar 28.
10
Undruggable KRAS-time to rebrand?不可成药的KRAS——是时候重新定义了？
Lancet Oncol. 2021 Mar;22(3):289. doi: 10.1016/S1470-2045(21)00091-7.

引用本文的文献

1
Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways.乔鲁纳霉素A通过调节KRAS介导的生存途径，诱导胰腺导管腺癌细胞、球体和患者来源的类器官发生凋亡。
Sci Rep. 2025 Apr 3;15(1):11376. doi: 10.1038/s41598-025-95766-5.
2
Computational design and validation of effective siRNAs to silence oncogenic KRAS.用于沉默致癌性KRAS的有效小干扰RNA的计算设计与验证
3 Biotech. 2023 Nov;13(11):350. doi: 10.1007/s13205-023-03767-w. Epub 2023 Sep 29.
3
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.

本文引用的文献

1
A bright future for KRAS inhibitors.KRAS抑制剂的光明未来。
Nat Cancer. 2020 Jan;1(1):25-27. doi: 10.1038/s43018-019-0016-8.
2
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?KRAS G12C 权游，谁是 KRAS 抑制剂的铁王座之王？
Cancer Treat Rev. 2020 Mar;84:101974. doi: 10.1016/j.ctrv.2020.101974. Epub 2020 Jan 23.
3
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.快速非均匀适应构象特异性 KRAS(G12C)抑制。
靶向“不可成药”蛋白的最新进展：从药物发现到临床试验。
Signal Transduct Target Ther. 2023 Sep 6;8(1):335. doi: 10.1038/s41392-023-01589-z.
4
Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles.多种癌症逃避多种 MAPK 通路抑制剂，并利用 DNA 复制应激信号来耐受异常细胞周期。
Sci Signal. 2023 Aug;16(796):eade8744. doi: 10.1126/scisignal.ade8744. Epub 2023 Aug 1.
5
Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma.通过生物信息学分析在索托拉西布耐药性胰腺导管腺癌中发现的潜在生物标志物。
Front Med (Lausanne). 2023 Jun 15;10:1107128. doi: 10.3389/fmed.2023.1107128. eCollection 2023.
6
Targeting Ras with protein engineering.利用蛋白质工程靶向 Ras。
Oncotarget. 2023 Jul 1;14:672-687. doi: 10.18632/oncotarget.28469.
7
RAS degraders: The new frontier for RAS-driven cancers.RAS 降解剂：RAS 驱动型癌症的新前沿。
Mol Ther. 2023 Jul 5;31(7):1904-1919. doi: 10.1016/j.ymthe.2023.03.017. Epub 2023 Mar 21.
8
Genetic differences between smokers and never-smokers with lung cancer.肺癌患者中吸烟者和不吸烟者的遗传差异。
Front Immunol. 2023 Feb 2;14:1063716. doi: 10.3389/fimmu.2023.1063716. eCollection 2023.
9
Evaluation of AMG510 Therapy on -Mutant Non-Small Cell Lung Cancer and Colorectal Cancer Cell Using a 3D Invasive Tumor Spheroid System under Normoxia and Hypoxia.在常氧和缺氧条件下，使用三维侵袭性肿瘤球体系统评估AMG510对KRAS突变型非小细胞肺癌和结肠直肠癌细胞的治疗效果。
Bioengineering (Basel). 2022 Dec 12;9(12):792. doi: 10.3390/bioengineering9120792.
10
Synthetic Vulnerabilities in the KRAS Pathway.KRAS 信号通路中的合成脆弱性
Cancers (Basel). 2022 Jun 8;14(12):2837. doi: 10.3390/cancers14122837.
Nature. 2020 Jan;577(7790):421-425. doi: 10.1038/s41586-019-1884-x. Epub 2020 Jan 8.
4
Discovery of a Covalent Inhibitor of KRAS (AMG 510) for the Treatment of Solid Tumors.发现 KRAS（AMG 510）共价抑制剂用于治疗实体瘤。
J Med Chem. 2020 Jan 9;63(1):52-65. doi: 10.1021/acs.jmedchem.9b01180. Epub 2019 Dec 24.
5
Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS.具有 d-氨基酸的合成烃 stapled SOS1 螺旋对表达 KRAS 的 H358 癌细胞的选择性凋亡诱导活性。
Eur J Med Chem. 2020 Jan 1;185:111844. doi: 10.1016/j.ejmech.2019.111844. Epub 2019 Nov 2.
6
Small molecule combats cancer-causing KRAS protein at last.小分子终于攻克致癌KRAS蛋白。
Nature. 2019 Nov;575(7782):294-295. doi: 10.1038/d41586-019-03242-8.
7
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.临床 KRAS(G12C) 抑制剂 AMG 510 可引发抗肿瘤免疫。
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
8
The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.KRAS 抑制剂 MRTX849 为 KRAS 突变型癌症在小鼠模型和患者中的治疗敏感性提供了新的见解。
Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28.
9
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.开发联合疗法以最大限度地提高肺癌中 KRAS-G12C 抑制剂的疗效。
Sci Transl Med. 2019 Sep 18;11(510). doi: 10.1126/scitranslmed.aaw7999.
10
Drugging an undruggable pocket on KRAS.靶向 KRAS“不可成药”口袋。
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15823-15829. doi: 10.1073/pnas.1904529116. Epub 2019 Jul 22.